相关实验视频

Updated: Feb 20, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

在多发性骨髓瘤中准BCMA,使用三功能NK细胞参与者

Alexandre Tang¹, Laurent Gauthier², Elisa Zaghi¹

¹Sanofi Immuno-Oncology Research, Vitry-sur-Seine, France.

Cell reports. Medicine

|February 19, 2026

概括

自然杀手细胞参与者为多发性骨髓瘤 (MM) 提供了一个有前途的新疗法. SAR445514是一种新的NK细胞激活剂,对MM细胞具有强大的抗瘤活性,副作用最小.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
血液学血液学血液学

背景情况:

多发性骨髓瘤 (MM) 是一种普遍存在的,无法治愈的血液性恶性瘤.
迫切需要持久有效的治疗策略.
自然杀手 (NK) 细胞参与剂 (NKCE) 正在成为基于T细胞的疗法的一个有希望的替代品,因为它们具有强大的抗瘤活性和减少细胞因子的释放.

研究的目的:

为了评估SAR445514,三功能NKCE针对MM细胞的BCMA,并在NK细胞上激活NKp46和FcγRIIIa.
在临床前模型中评估SAR445514的抗瘤有效性和安全性.
研究SAR445514在激活患者衍生的NK细胞对自身恶性细胞的潜力.

主要方法:

探索SAR445514的各种分子格式,重点关注BCMA和NKp46的价值.
在体外和体内研究以确定抗瘤活性和细胞因子释放.
使用来自MM患者的外周血液单核细胞对NK细胞激活和细胞毒性的活体分析.

主要成果:

SAR445514是一种单价NKCE,表现出增强的抗体依赖细胞细胞毒性 (ADCC).
该药物在体外和体内表现出强大和选择性的抗瘤活性,超过其他FcγRIIIa免疫细胞参与剂.
与T细胞参与者相比,SAR445514观察到最小的细胞因子释放.
活体研究表明NK细胞有效激活和细胞毒性对自身的MM细胞,包括治疗耐药的病例.

结论:

SAR445514显示出显著的临床前疗效,作为多发性骨髓瘤的NKCE.
它能够激活患者NK细胞和向恶性细胞的能力支持其治疗潜力.
这些发现为SAR445514的持续临床开发提供了强有力的理由.

关键词:

这就是为什么BCMABCMABCMA.参与NK细胞参与者.它具有抗瘤活性.活体骨髓出口骨髓多发性骨髓瘤是多发性骨髓瘤的一种.临床前模型的临床前模型这是一种三功能抗体.

更多相关视频

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.